NO304576B1 - FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom - Google Patents

FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom Download PDF

Info

Publication number: NO304576B1
Authority: NO; Norway
Prior art keywords: compounds; biologically active; group; encapsulated; lipid
Prior art date: 1990-03-21

Application number

NO923624A

Other languages

English (en)

Norwegian (no)

Other versions

NO923624L (no

NO923624D0 (no

Inventor

Sinil Kim

Original Assignee

Depotech Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-21

Filing date

1992-09-17

Publication date

1999-01-18

1992-09-17 Application filed by Depotech Corp filed Critical Depotech Corp

1992-09-17 Publication of NO923624L publication Critical patent/NO923624L/no

1992-09-17 Publication of NO923624D0 publication Critical patent/NO923624D0/no

1999-01-18 Publication of NO304576B1 publication Critical patent/NO304576B1/no

Links

239000002502 liposome Substances 0.000 title claims abstract description 66
150000002632 lipids Chemical class 0.000 title claims abstract description 39
238000000034 method Methods 0.000 title claims abstract description 36
239000000839 emulsion Substances 0.000 claims abstract description 29
239000000203 mixture Substances 0.000 claims abstract description 22
150000001875 compounds Chemical class 0.000 claims description 65
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
239000007762 w/o emulsion Substances 0.000 claims description 22
239000003960 organic solvent Substances 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
239000002904 solvent Substances 0.000 claims description 15
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
239000008103 glucose Substances 0.000 claims description 13
239000012458 free base Substances 0.000 claims description 10
229960003646 lysine Drugs 0.000 claims description 7
235000012000 cholesterol Nutrition 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
239000004472 Lysine Substances 0.000 claims description 5
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
229910001873 dinitrogen Inorganic materials 0.000 claims description 5
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
238000001704 evaporation Methods 0.000 claims description 4
150000003840 hydrochlorides Chemical class 0.000 claims description 4
230000003472 neutralizing effect Effects 0.000 claims description 4
150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 4
102000004169 proteins and genes Human genes 0.000 claims description 4
108090000623 proteins and genes Proteins 0.000 claims description 4
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 3
230000008020 evaporation Effects 0.000 claims description 3
229930195733 hydrocarbon Natural products 0.000 claims description 3
150000002430 hydrocarbons Chemical class 0.000 claims description 3
229960005337 lysine hydrochloride Drugs 0.000 claims description 3
230000007935 neutral effect Effects 0.000 claims description 3
239000003921 oil Substances 0.000 claims description 3
108060001064 Calcitonin Proteins 0.000 claims description 2
102000055006 Calcitonin Human genes 0.000 claims description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
241001465754 Metazoa Species 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
239000011149 active material Substances 0.000 claims description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
229960004015 calcitonin Drugs 0.000 claims description 2
239000003925 fat Substances 0.000 claims description 2
235000019197 fats Nutrition 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
229960000485 methotrexate Drugs 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
229930003799 tocopherol Natural products 0.000 claims description 2
239000011732 tocopherol Substances 0.000 claims description 2
150000003611 tocopherol derivatives Chemical class 0.000 claims description 2
235000019149 tocopherols Nutrition 0.000 claims description 2
150000003626 triacylglycerols Chemical class 0.000 claims description 2
235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
239000008158 vegetable oil Substances 0.000 claims description 2
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 2
150000003904 phospholipids Chemical class 0.000 claims 5
238000000889 atomisation Methods 0.000 claims 3
QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
239000000159 acid neutralizing agent Substances 0.000 claims 2
238000013019 agitation Methods 0.000 claims 2
150000002170 ethers Chemical class 0.000 claims 2
229960001031 glucose Drugs 0.000 claims 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
-1 sphingomyelin Chemical compound 0.000 claims 2
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims 1
WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
108010006654 Bleomycin Proteins 0.000 claims 1
108010001857 Cell Surface Receptors Proteins 0.000 claims 1
108010092160 Dactinomycin Proteins 0.000 claims 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
102000003886 Glycoproteins Human genes 0.000 claims 1
108090000288 Glycoproteins Proteins 0.000 claims 1
102000014150 Interferons Human genes 0.000 claims 1
108010050904 Interferons Proteins 0.000 claims 1
102000000588 Interleukin-2 Human genes 0.000 claims 1
108010002350 Interleukin-2 Proteins 0.000 claims 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
108010000817 Leuprolide Proteins 0.000 claims 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical class C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
229930183665 actinomycin Natural products 0.000 claims 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
150000001413 amino acids Chemical class 0.000 claims 1
229940035676 analgesics Drugs 0.000 claims 1
239000000730 antalgic agent Substances 0.000 claims 1
230000003288 anthiarrhythmic effect Effects 0.000 claims 1
230000001088 anti-asthma Effects 0.000 claims 1
230000001093 anti-cancer Effects 0.000 claims 1
230000003178 anti-diabetic effect Effects 0.000 claims 1
230000000843 anti-fungal effect Effects 0.000 claims 1
230000002959 anti-hypotensive effect Effects 0.000 claims 1
230000002141 anti-parasite Effects 0.000 claims 1
230000000840 anti-viral effect Effects 0.000 claims 1
239000003416 antiarrhythmic agent Substances 0.000 claims 1
239000000924 antiasthmatic agent Chemical class 0.000 claims 1
239000003472 antidiabetic agent Chemical class 0.000 claims 1
229940121375 antifungal agent Drugs 0.000 claims 1
239000002220 antihypertensive agent Substances 0.000 claims 1
229940124572 antihypotensive agent Drugs 0.000 claims 1
239000003096 antiparasitic agent Chemical class 0.000 claims 1
230000003115 biocidal effect Effects 0.000 claims 1
229960001561 bleomycin Drugs 0.000 claims 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
230000000903 blocking effect Effects 0.000 claims 1
229940077731 carbohydrate nutrients Drugs 0.000 claims 1
150000001720 carbohydrates Chemical class 0.000 claims 1
235000014633 carbohydrates Nutrition 0.000 claims 1
229940097217 cardiac glycoside Drugs 0.000 claims 1
239000002368 cardiac glycoside Substances 0.000 claims 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
229960004316 cisplatin Drugs 0.000 claims 1
229960000975 daunorubicin Drugs 0.000 claims 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
229960004679 doxorubicin Drugs 0.000 claims 1
238000004945 emulsification Methods 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 1
229960000961 floxuridine Drugs 0.000 claims 1
229960002949 fluorouracil Drugs 0.000 claims 1
150000008282 halocarbons Chemical class 0.000 claims 1
230000001024 immunotherapeutic effect Effects 0.000 claims 1
229940079322 interferon Drugs 0.000 claims 1
239000008101 lactose Substances 0.000 claims 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
229960004338 leuprorelin Drugs 0.000 claims 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
229960001924 melphalan Drugs 0.000 claims 1
102000006240 membrane receptors Human genes 0.000 claims 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
229960001428 mercaptopurine Drugs 0.000 claims 1
229960001156 mitoxantrone Drugs 0.000 claims 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
150000007523 nucleic acids Chemical class 0.000 claims 1
102000039446 nucleic acids Human genes 0.000 claims 1
108020004707 nucleic acids Proteins 0.000 claims 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
150000003905 phosphatidylinositols Chemical class 0.000 claims 1
229940125723 sedative agent Drugs 0.000 claims 1
239000000932 sedative agent Substances 0.000 claims 1
239000007921 spray Substances 0.000 claims 1
229930002534 steroid glycoside Natural products 0.000 claims 1
150000008143 steroidal glycosides Chemical class 0.000 claims 1
150000003431 steroids Chemical class 0.000 claims 1
229960001052 streptozocin Drugs 0.000 claims 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
229960001196 thiotepa Drugs 0.000 claims 1
229960003087 tioguanine Drugs 0.000 claims 1
MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
229960005486 vaccine Drugs 0.000 claims 1
229960003048 vinblastine Drugs 0.000 claims 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
229960004528 vincristine Drugs 0.000 claims 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 9
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 9
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 9
229940117972 triolein Drugs 0.000 description 9
239000000725 suspension Substances 0.000 description 6
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 5
BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
229940093609 tricaprylin Drugs 0.000 description 4
VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 4
238000005538 encapsulation Methods 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
229940067605 phosphatidylethanolamines Drugs 0.000 description 3
150000008106 phosphatidylserines Chemical class 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 2
TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
SKBXVAOMEVOTGJ-UHFFFAOYSA-N xi-Pinol Chemical compound CC1=CCC2C(C)(C)OC1C2 SKBXVAOMEVOTGJ-UHFFFAOYSA-N 0.000 description 2
229960000523 zalcitabine Drugs 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108010004250 Inhibins Proteins 0.000 description 1
102000002746 Inhibins Human genes 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
108010047386 Pituitary Hormones Proteins 0.000 description 1
102000006877 Pituitary Hormones Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
238000010952 in-situ formation Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000893 inhibin Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
239000000047 product Substances 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Manufacturing Of Micro-Capsules (AREA)
Saccharide Compounds (AREA)

NO923624A 1990-03-21 1992-09-17 FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom NO304576B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49684690A	1990-03-21	1990-03-21
PCT/US1991/001849 WO1991014445A1 (en)	1990-03-21	1991-03-20	Heterovesicular liposomes

Publications (3)

Publication Number	Publication Date
NO923624L NO923624L (no)	1992-09-17
NO923624D0 NO923624D0 (no)	1992-09-17
NO304576B1 true NO304576B1 (no)	1999-01-18

Family

ID=23974416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO923624A NO304576B1 (no)	1990-03-21	1992-09-17	FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom

Country Status (20)

Country	Link
EP (1)	EP0524968B1 (de)
JP (1)	JP3461000B2 (de)
KR (1)	KR100203223B1 (de)
CN (1)	CN1053101C (de)
AT (1)	ATE123412T1 (de)
AU (1)	AU655177B2 (de)
CA (1)	CA2078666C (de)
DE (1)	DE69110281T2 (de)
DK (1)	DK0524968T3 (de)
ES (1)	ES2073164T3 (de)
FI (1)	FI104464B (de)
IE (1)	IE62772B1 (de)
IL (1)	IL97615A (de)
NO (1)	NO304576B1 (de)
NZ (1)	NZ237464A (de)
PT (1)	PT97101B (de)
RU (1)	RU2120795C1 (de)
SA (1)	SA93130496B1 (de)
WO (1)	WO1991014445A1 (de)
ZA (1)	ZA911974B (de)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3278273B2 (ja) *	1993-12-17	2002-04-30	キヤノン株式会社	薬剤徐放性カプセル
US6544523B1 (en)	1996-11-13	2003-04-08	Chiron Corporation	Mutant forms of Fas ligand and uses thereof
EP1935901A1 (de)	1996-12-13	2008-06-25	Novartis Vaccines and Diagnostics, Inc.	Analyse und Trennung von PDGF-Proteinen
US5985214A (en)	1997-05-16	1999-11-16	Aurora Biosciences Corporation	Systems and methods for rapidly identifying useful chemicals in liquid samples
CA2304096C (en)	1997-09-18	2003-09-09	Pacira Pharmaceuticals, Inc.	Sustained-release liposomal anesthetic compositions
CA2671261A1 (en)	1997-11-06	1999-05-20	Novartis Vaccines And Diagnostics S.R.L.	Neisserial antigens
AU752802C (en)	1997-11-14	2006-04-13	Pacira Pharmaceuticals, Inc.	Production of multivesicular liposomes
EP1047784B2 (de)	1998-01-14	2015-03-18	Novartis Vaccines and Diagnostics S.r.l.	Antigene aus neisseria meningitidis
EP2261338A3 (de)	1998-05-01	2012-01-04	Novartis Vaccines and Diagnostics, Inc.	Antigene und Zusammensetzungen gegen Neisseria meningitidis
ATE386804T1 (de)	1998-10-15	2008-03-15	Novartis Vaccines & Diagnostic	Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
EP1961813B1 (de)	1998-12-16	2011-08-10	Novartis Vaccines and Diagnostics, Inc.	Menschliche Cyclin-abhängige Kinase (hPNQALRE)
US7393823B1 (en)	1999-01-20	2008-07-01	Oregon Health And Science University	HER-2 binding antagonists
US7625859B1 (en)	2000-02-16	2009-12-01	Oregon Health & Science University	HER-2 binding antagonists
WO2000066741A2 (en)	1999-04-30	2000-11-09	Chiron S.P.A.	Conserved neisserial antigens
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
JP2004508801A (ja)	1999-10-29	2004-03-25	カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ	ナイセリア抗原性ペプチド
EP2163626A1 (de)	1999-11-18	2010-03-17	Novartis Vaccines and Diagnostics, Inc.	Menschliches FGF-21 Gen und Genexpressionsprodukte
PT2289545T (pt)	2000-01-17	2016-09-06	Glaxosmithkline Biologicals Sa	Vacina de omv suplementada contra meningococos
WO2001066595A2 (en)	2000-03-08	2001-09-13	Chiron Corporation	Human fgf-23 gene and gene expression products
EP1950297A2 (de)	2000-05-31	2008-07-30	Novartis Vaccines and Diagnostics, Inc.	Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
US7700359B2 (en)	2000-06-02	2010-04-20	Novartis Vaccines And Diagnostics, Inc.	Gene products differentially expressed in cancerous cells
WO2003057926A1 (en)	2002-01-08	2003-07-17	Chiron Corporation	Gene products differentially expressed in cancerous breast cells and their methods of use
ES2305087T3 (es)	2000-06-15	2008-11-01	Novartis Vaccines And Diagnostics, Inc.	Polinucleotidos relacionados con el cancer de colon.
CA2881568C (en)	2000-10-27	2019-09-24	Novartis Vaccines And Diagnostics, Inc.	Nucleic acids and proteins from streptococcus groups a & b
JP2004535765A (ja)	2000-12-07	2004-12-02	カイロンコーポレイション	前立腺癌においてアップレギュレートされた内因性レトロウイルス
GB0107661D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Staphylococcus aureus
GB0107658D0 (en)	2001-03-27	2001-05-16	Chiron Spa	Streptococcus pneumoniae
AU2002258728A1 (en)	2001-04-06	2002-10-21	Georgetown University	Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en)	2001-04-06	2002-10-17	Georgetown University	Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en)	2001-04-06	2002-10-17	Georgetown University	Gene brcc2 and diagnostic and therapeutic uses thereof
US7309783B2 (en)	2001-05-09	2007-12-18	The University Of Connecticut	Mammalian early developmental regulator gene
EP1404713A4 (de)	2001-05-24	2004-09-22	Human Dna Technology Inc	Neues keratinocyte growth factor 2 analogon in haarfollikeln
WO2003039491A2 (en)	2001-11-09	2003-05-15	Georgetown University	Novel isoforms of vascular endothelial cell growth inhibitor
RU2331435C2 (ru)	2001-12-12	2008-08-20	Чирон Срл.	Иммунизация против chlamydia trachomatis
EP2093233A1 (de)	2002-03-21	2009-08-26	Sagres Discovery, Inc.	Neue Zusammensetzungen und Verfahren bei Krebs
US7138512B2 (en)	2002-04-10	2006-11-21	Georgetown University	Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en)	2002-04-10	2007-07-17	Georgetown University	Gene shinc-3 and diagnostic and therapeutic uses thereof
US8518694B2 (en)	2002-06-13	2013-08-27	Novartis Vaccines And Diagnostics, Inc.	Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
US7135324B2 (en)	2002-09-04	2006-11-14	The University Of Connecticut	Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en)	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
ZA200502612B (en)	2002-10-08	2007-07-25	Rinat Neuroscience Corp	Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
WO2005000194A2 (en)	2002-10-08	2005-01-06	Rinat Neuroscience Corp.	Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
EP1562982B1 (de)	2002-11-15	2010-05-05	Novartis Vaccines and Diagnostics S.r.l.	Unerwartete oberflächenproteine in neisseria meningitidis
RU2239416C2 (ru) *	2002-12-15	2004-11-10	Ставропольский научно-исследовательский противочумный институт	Способ лечения бруцеллеза
RU2234311C1 (ru) *	2002-12-15	2004-08-20	Ставропольский научно-исследовательский противочумный институт	Способ лечения бруцеллеза
DK2270048T3 (en)	2002-12-24	2016-01-18	Rinat Neuroscience Corp	Anti-NGF antibodies and methods for their use
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
US9498530B2 (en)	2002-12-24	2016-11-22	Rinat Neuroscience Corp.	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7767387B2 (en)	2003-06-13	2010-08-03	Sagres Discovery, Inc.	Therapeutic targets in cancer
US20040170982A1 (en)	2003-02-14	2004-09-02	Morris David W.	Novel therapeutic targets in cancer
JP2007524362A (ja)	2003-02-14	2007-08-30	サイグレスディスカバリー，インコーポレイテッド	癌における治療ｇｐｃｒ標的
BRPI0407375A (pt)	2003-02-19	2006-02-07	Rinat Neuroscience Corp	Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
RU2378830C2 (ru) *	2003-08-22	2010-01-20	Даниско А/С	Инкапсулированный антимикробный материал
GB2388581A (en)	2003-08-22	2003-11-19	Danisco	Coated aqueous beads
ES2481167T3 (es)	2003-08-22	2014-07-29	Dupont Nutrition Biosciences Aps	Composición que comprende una bacteriocina y un extracto de una planta de la familia Labiatae
AP2006003670A0 (en)	2003-12-23	2006-06-30	Rinat Neuroscience Corp	Agonist anti-TRKC antibodies and methods using same
JP4792390B2 (ja)	2004-03-29	2011-10-12	株式会社ガルファーマ	新規ガレクチン９改変体タンパク質及びその用途
EP3372614B1 (de)	2004-04-07	2022-06-08	Rinat Neuroscience Corp.	Verfahren zur schmerzbehandlung in knochenkrebs durch verabreichung eines ngf-antagonististen
AU2005327194B2 (en)	2004-07-09	2010-09-09	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Soluble forms of Hendra and Nipah virus G glycoprotein
US20060024677A1 (en)	2004-07-20	2006-02-02	Morris David W	Novel therapeutic targets in cancer
MX2007000998A (es)	2004-07-30	2007-07-11	Rinat Neuroscience Corp	Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
US7619007B2 (en)	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
CA2588295C (en)	2004-11-23	2013-10-22	Adamas Pharma, Llc	Method and composition for administering an nmda receptor antagonist to a subject
EP2623099A1 (de)	2004-11-24	2013-08-07	Neuromolecular Pharmaceuticals, Inc	Zusammensetzung und Verfahren zur Behandlung neurologischer Erkrankungen
US7939490B2 (en)	2004-12-13	2011-05-10	University Of Maryland, Baltimore	TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
JP2008530245A (ja)	2005-02-18	2008-08-07	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	尿路病原性菌株由来の抗原
ATE481096T1 (de)	2005-04-06	2010-10-15	Adamas Pharmaceuticals Inc	Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
EP1865981A2 (de)	2005-04-07	2007-12-19	Chiron Corporation	Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
CA2604844A1 (en)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics, Inc.	Cancer-related genes
UY29504A1 (es)	2005-04-29	2006-10-31	Rinat Neuroscience Corp	Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EP1907425B1 (de)	2005-07-22	2014-01-08	Y's Therapeutics Co., Ltd.	Anti-cd26-antikörper und verfahren zu ihrer verwendung
EP3069731A1 (de)	2005-11-14	2016-09-21	Labrys Biologics Inc.	Antagonistische antikörper gegen calcitoningen-assoziiertes peptid und verfahren damit
JP2009525319A (ja)	2006-02-02	2009-07-09	ライナットニューロサイエンスコーポレイション	ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
RU2330664C2 (ru) *	2006-04-26	2008-08-10	Александр Иванович Арчаков	Лекарственный препарат и способ лечения ревматических заболеваний
CA2652703C (en)	2006-06-07	2018-08-28	Bioalliance C.V.	Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
PT2054431E (pt)	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
EP2586790A3 (de)	2006-08-16	2013-08-14	Novartis AG	Immunogene von uropathogenen Escherichia coli
WO2008116032A1 (en)	2007-03-21	2008-09-25	Effat Emamian	Compositions and methods for inhibiting tumor cell growth
US20100261640A1 (en)	2007-04-10	2010-10-14	Branco Luis M	Soluble and membrane anchored forms of lassa virus subunit proteins
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
BRPI0822049B1 (pt)	2007-12-17	2021-11-16	Pfizer Limited	Composiqao farmaceutica compreendendo anticorpo antagonista anti-ngf, kit e uso de um anticorpo antingf
HUE026846T2 (en)	2007-12-18	2016-08-29	Bioalliance Cv	Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
RU2367443C1 (ru) *	2008-02-28	2009-09-20	Общество с ограниченной ответственностью "Битеп"	Средство на основе природных фосфолипидов
EP3023502A1 (de)	2008-04-10	2016-05-25	Cell Signaling Technology, Inc.	Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
WO2009150623A1 (en)	2008-06-13	2009-12-17	Pfizer Inc	Treatment of chronic prostatitis
TWI516501B (zh)	2008-09-12	2016-01-11	禮納特神經系統科學公司	Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (en)	2009-02-02	2010-08-05	Rinat Neuroscience Corporation	Agonist anti-trkb monoclonal antibodies
US8568732B2 (en)	2009-03-06	2013-10-29	Novartis Ag	Chlamydia antigens
WO2010118243A2 (en)	2009-04-08	2010-10-14	Genentech, Inc.	Use of il-27 antagonists to treat lupus
EP3263128A3 (de)	2009-04-14	2018-01-24	GlaxoSmithKline Biologicals S.A.	Zusammensetzungen zur immunisierung gegen staphylococcus aureus
WO2010146511A1 (en)	2009-06-17	2010-12-23	Pfizer Limited	Treatment of overactive bladder
US10988511B2 (en)	2009-07-07	2021-04-27	Glaxosmithkline Biologicals Sa	Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
AU2010272243A1 (en)	2009-07-16	2012-03-08	Novartis Ag	Detoxified Escherichia coli immunogens
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
CA2994873A1 (en)	2009-12-02	2011-06-09	Adamas Pharma, Llc	Amantadine compositions and methods of use
AR080291A1 (es)	2010-02-24	2012-03-28	Rinat Neuroscience Corp	Anticuerpos antagonistas anti receptor de il-7 y procedimientos
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
JP5932670B2 (ja)	2010-03-11	2016-06-08	ライナットニューロサイエンスコーポレイション	ｐＨ依存性の抗原結合を有する抗体
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
US9770414B2 (en) *	2010-05-13	2017-09-26	Pacira Pharmaceuticals, Inc.	Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
JP2013533286A (ja)	2010-07-30	2013-08-22	セントルイスユニバーシティ	疼痛を治療する方法
WO2012072769A1 (en)	2010-12-01	2012-06-07	Novartis Ag	Pneumococcal rrgb epitopes and clade combinations
US20130071375A1 (en)	2011-08-22	2013-03-21	Saint Louis University	Compositions and methods for treating inflammation
WO2013028527A1 (en)	2011-08-23	2013-02-28	Indiana University Research And Technology Corporation	Compositions and methods for treating cancer
TWI495644B (zh)	2011-11-11	2015-08-11	Rinat Neuroscience Corp	營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
US9249224B2 (en)	2011-12-22	2016-02-02	Rinat Neuroscience Corp.	Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (en)	2011-12-22	2013-06-27	Rinat Neuroscience Corp.	Staphylococcus aureus specific antibodies and uses thereof
CA2877948C (en)	2012-07-02	2019-07-30	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Paramyxovirus and methods of use
US8603470B1 (en)	2012-08-07	2013-12-10	National Cheng Kung University	Use of IL-20 antagonists for treating liver diseases
CA2890483A1 (en)	2012-11-09	2014-05-15	Robert ARCH	Platelet-derived growth factor b specific antibodies and compositions and uses thereof
AU2014240045A1 (en)	2013-03-15	2015-09-10	Dyax Corp.	Anti-plasma kallikrein antibodies
WO2014181229A2 (en)	2013-05-07	2014-11-13	Rinat Neuroscience Corp.	Anti-glucagon receptor antibodies and methods of use thereof
US10154971B2 (en)	2013-06-17	2018-12-18	Adamas Pharma, Llc	Methods of administering amantadine
US10208125B2 (en)	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
CA2919790C (en)	2013-08-02	2018-06-19	Pfizer Inc.	Anti-cxcr4 antibodies and antibody-drug conjugates
US9683998B2 (en)	2013-11-13	2017-06-20	Pfizer Inc.	Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
WO2015087187A1 (en)	2013-12-10	2015-06-18	Rinat Neuroscience Corp.	Anti-sclerostin antibodies
WO2015109212A1 (en)	2014-01-17	2015-07-23	Pfizer Inc.	Anti-il-2 antibodies and compositions and uses thereof
AU2015230933B2 (en)	2014-03-21	2020-08-13	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10428158B2 (en)	2014-03-27	2019-10-01	Dyax Corp.	Compositions and methods for treatment of diabetic macular edema
WO2015168474A1 (en)	2014-04-30	2015-11-05	President And Fellows Of Harvard College	Fusion proteins for treating cancer and related methods
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
TWI595006B (zh)	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
CN107405399B (zh)	2015-01-02	2022-02-08	武田药品工业株式会社	针对血浆激肽释放酶和因子xii的双特异性抗体
US9758575B2 (en)	2015-04-06	2017-09-12	Yung Shin Pharmaceutical Industrial Co. Ltd.	Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
TWI703159B (zh)	2015-04-13	2020-09-01	美商輝瑞股份有限公司	Bcma特異性治療性抗體及其用途
AU2016297018B9 (en)	2015-07-21	2022-12-01	Takeda Pharmaceutical Company Limited	A monoclonal antibody inhibitor of factor XIIa
WO2017015334A1 (en)	2015-07-21	2017-01-26	Saint Louis University	Compositions and methods for diagnosing and treating endometriosis-related infertility
US11066481B2 (en)	2015-07-23	2021-07-20	The Regents Of The University Of California	Antibodies to coagulation factor XIa and uses thereof
KR102438650B1 (ko)	2015-08-19	2022-08-31	화이자 인코포레이티드	조직 인자 경로 억제제 항체 및 그의 용도
HRP20211081T1 (hr)	2015-09-15	2021-10-15	Scholar Rock, Inc.	Anti-pro/latentna miostatinska protutijela i njihove uporabe
JP6661319B2 (ja) *	2015-09-28	2020-03-11	小林製薬株式会社	リポソーム
CN115636880A (zh)	2015-10-23	2023-01-24	辉瑞有限公司	抗il-2抗体及其组合物和用途
WO2017075037A1 (en)	2015-10-27	2017-05-04	Scholar Rock, Inc.	Primed growth factors and uses thereof
CN106699889A (zh)	2015-11-18	2017-05-24	礼进生物医药科技（上海）有限公司	抗pd-1抗体及其治疗用途
CN109069480A (zh)	2015-12-30	2018-12-21	阿达玛斯医药公司	用于治疗与癫痫相关的病症的方法和组合物
KR20250057128A (ko)	2015-12-30	2025-04-28	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
CN109219618B (zh)	2016-01-21	2022-08-09	辉瑞大药厂	针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
KR102069680B1 (ko) *	2017-03-02	2020-01-23	단디바이오사이언스 주식회사	면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
CA3054885A1 (en)	2017-03-03	2018-09-07	Rinat Neuroscience Corp.	Anti-gitr antibodies and methods of use thereof
WO2018167621A1 (en)	2017-03-16	2018-09-20	Pfizer Inc.	Tyrosine prototrophy
CA3059938A1 (en)	2017-04-14	2018-10-18	Kodiak Sciences Inc.	Complement factor d antagonist antibodies and conjugates thereof
EP3615570A4 (de)	2017-04-25	2021-02-24	LBL Biotechnology Inc.	Verwendung von il-20-antagonisten zur behandlung von augenerkrankungen
WO2018200885A1 (en)	2017-04-26	2018-11-01	Neurocentria, Inc.	Magnesium compositions and methods of use
MY201312A (en)	2017-06-02	2024-02-16	Pfizer	Antibodies specific for flt3 and their uses
GB202209539D0 (en)	2017-06-13	2022-08-10	Bostongene Corp	Systems and methods for identifying cancer treatments from normalized biomarker scores
US20190015473A1 (en)	2017-07-13	2019-01-17	Massachusetts Institute Of Technology	Targeting the hdac2-sp3 complex to enhance synaptic funcation
WO2019016784A1 (en)	2017-07-21	2019-01-24	Universidade De Coimbra	ANTI-NUCLEOLIN ANTIBODIES
EP3692370A2 (de)	2017-10-04	2020-08-12	OPKO Pharmaceuticals, LLC	Artikel und verfahren zur personalisierten krebstherapie
CA3080120C (en)	2017-10-27	2023-11-21	New York University	Anti-galectin-9 antibodies and uses thereof
CN112020518A (zh)	2018-02-01	2020-12-01	辉瑞公司	靶向cd70的嵌合抗原受体
PE20210708A1 (es)	2018-02-01	2021-04-16	Pfizer	Anticuerpos especificos para cd70 y sus usos
AU2019228381B2 (en)	2018-02-28	2021-12-16	Pfizer Inc.	IL-15 variants and uses thereof
EP3758737A4 (de)	2018-03-02	2022-10-12	Kodiak Sciences Inc.	Il-6-antikörper und fusionskonstrukte und konjugate davon
KR102602329B1 (ko)	2018-05-23	2023-11-16	화이자 인코포레이티드	Cd3에 특이적인 항체 및 이의 용도
MX2020012607A (es)	2018-05-23	2021-01-29	Pfizer	Anticuerpos especificos para gucy2c y sus usos.
JP7603580B2 (ja)	2018-10-15	2024-12-20	エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド	顆粒球マクロファージコロニー刺激因子に対する抗体及びそれらの使用
WO2020132190A1 (en)	2018-12-21	2020-06-25	Multitude Inc.	Antibodies specific to muc18
US12084500B2 (en)	2019-01-23	2024-09-10	New York University	Antibodies specific to delta 1 chain of T cell receptor
US12205675B2 (en)	2019-07-03	2025-01-21	Bostongene Corporation	Techniques for bias correction in sequence data
WO2021071830A1 (en)	2019-10-07	2021-04-15	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
WO2021072244A1 (en)	2019-10-11	2021-04-15	Beth Israel Deaconess Medical Center, Inc.	Anti-tn antibodies and uses thereof
US20230067811A1 (en)	2020-01-24	2023-03-02	University Of Virginia Patent Foundation	Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en)	2020-04-08	2021-10-14	Pfizer Inc.	Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en)	2020-05-06	2021-11-11	Crispr Therapeutics Ag	Mask peptides and masked anti-ptk7 antibodies comprising such
US20230235007A1 (en)	2020-06-15	2023-07-27	Ming-Che Shih	Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
MX2023000662A (es)	2020-07-17	2023-02-27	Pfizer	Anticuerpos terapeuticos y sus usos.
CA3190227A1 (en)	2020-07-30	2022-02-03	Pfizer Inc.	Cells having gene duplications and uses thereof
KR20230117327A (ko)	2020-09-03	2023-08-08	어빈 에스.와이. 첸	가용성 알칼리성 포스파타제 작제물 및 가용성 알칼리성 포스파타제 작제물을 인코딩하는 폴리뉴클레오티드를 포함하는 발현 벡터
US12254961B2 (en)	2020-12-04	2025-03-18	Bostongene Corporation	Hierarchical machine learning techniques for identifying molecular categories from expression data
US11357727B1 (en)	2021-01-22	2022-06-14	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en)	2021-01-22	2024-11-26	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en)	2021-01-22	2022-03-22	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en)	2021-01-22	2021-06-15	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
JP2024517745A (ja)	2021-04-29	2024-04-23	ボストンジーンコーポレイション	複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
CA3227875A1 (en)	2021-08-02	2023-02-09	Pfizer Inc.	Improved expression vectors and uses thereof
EP4415713A4 (de)	2021-10-14	2025-08-06	Pacira Pharmaceuticals Inc	Bupivacain-multivesikuläre liposomformulierungen und verwendungen davon
CA3249858A1 (en)	2022-01-31	2023-08-03	Bostongene Corporation	MACHINE LEARNING TECHNIQUES FOR CYTOMETRY
WO2023148598A1 (en)	2022-02-02	2023-08-10	Pfizer Inc.	Cysteine prototrophy
US20240029884A1 (en)	2022-07-15	2024-01-25	Bostongene Corporation	Techniques for detecting homologous recombination deficiency (hrd)
CN115957213A (zh) *	2022-12-30	2023-04-14	青岛市胶州中心医院	一种抗感染甲硝唑制剂及其制备方法
US20260120879A1 (en)	2023-10-31	2026-04-30	Bostongene Corporation	Machine learning technique for identifying ici responders and non-responders
WO2025157994A1 (en)	2024-01-25	2025-07-31	Intervet International B.V.	Vaccine against ruminant respiratory disease
US20250253011A1 (en)	2024-02-02	2025-08-07	Seven Bridges Genomics Inc.	Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
US12280149B1 (en)	2024-05-20	2025-04-22	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US12156940B1 (en)	2024-05-20	2024-12-03	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en)	2024-05-20	2025-03-18	Pacira Pharmaceuticals, Inc.	Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en) *	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
CA1237671A (en) *	1983-08-01	1988-06-07	Michael W. Fountain	Enhancement of pharmaceutical activity
EP0199362A3 (de) *	1985-04-26	1987-10-07	Massachusetts Institute Of Technology	System und Vorrichtung zur verzögerten und stossweisen Freisetzung biologisch aktiver Substanzen
FR2591105B1 (fr) *	1985-12-11	1989-03-24	Moet Hennessy Rech	Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
GB8704171D0 (en) *	1987-02-23	1987-04-01	Clayton Found Res	Multivesicular liposomes

1991
- 1991-03-18 ZA ZA911974A patent/ZA911974B/xx unknown
- 1991-03-18 NZ NZ237464A patent/NZ237464A/en unknown
- 1991-03-19 IE IE91191A patent/IE62772B1/en not_active IP Right Cessation
- 1991-03-20 AU AU75806/91A patent/AU655177B2/en not_active Ceased
- 1991-03-20 ES ES91906733T patent/ES2073164T3/es not_active Expired - Lifetime
- 1991-03-20 JP JP50728091A patent/JP3461000B2/ja not_active Expired - Lifetime
- 1991-03-20 WO PCT/US1991/001849 patent/WO1991014445A1/en not_active Ceased
- 1991-03-20 AT AT91906733T patent/ATE123412T1/de not_active IP Right Cessation
- 1991-03-20 DK DK91906733.0T patent/DK0524968T3/da active
- 1991-03-20 CA CA002078666A patent/CA2078666C/en not_active Expired - Lifetime
- 1991-03-20 EP EP91906733A patent/EP0524968B1/de not_active Expired - Lifetime
- 1991-03-20 DE DE69110281T patent/DE69110281T2/de not_active Expired - Lifetime
- 1991-03-20 IL IL9761591A patent/IL97615A/en not_active IP Right Cessation
- 1991-03-21 PT PT97101A patent/PT97101B/pt not_active IP Right Cessation
- 1991-03-21 CN CN91102478A patent/CN1053101C/zh not_active Expired - Fee Related
- 1991-03-21 RU SU5053129A patent/RU2120795C1/ru not_active IP Right Cessation
1992
- 1992-09-17 NO NO923624A patent/NO304576B1/no unknown
- 1992-09-18 FI FI924193A patent/FI104464B/fi active
- 1992-09-21 KR KR1019920702302A patent/KR100203223B1/ko not_active Expired - Fee Related
1993
- 1993-04-27 SA SA93130496A patent/SA93130496B1/ar unknown

Also Published As

Publication number	Publication date
FI924193L (fi)	1992-09-18
IE910911A1 (en)	1991-09-25
AU7580691A (en)	1991-10-21
CA2078666A1 (en)	1991-09-22
SA93130496B1 (ar)	2004-08-14
AU655177B2 (en)	1994-12-08
NO923624L (no)	1992-09-17
PT97101B (pt)	1998-08-31
NZ237464A (en)	1995-02-24
ZA911974B (en)	1994-08-22
DK0524968T3 (da)	1995-07-31
CN1055663A (zh)	1991-10-30
IE62772B1 (en)	1995-02-22
IL97615A (en)	1995-06-29
WO1991014445A1 (en)	1991-10-03
RU2120795C1 (ru)	1998-10-27
JPH05507680A (ja)	1993-11-04
IL97615A0 (en)	1992-06-21
DE69110281D1 (de)	1995-07-13
CN1053101C (zh)	2000-06-07
EP0524968A4 (en)	1993-03-24
NO923624D0 (no)	1992-09-17
EP0524968A1 (de)	1993-02-03
FI104464B (fi)	2000-02-15
CA2078666C (en)	2001-10-02
KR100203223B1 (ko)	1999-06-15
FI924193A0 (fi)	1992-09-18
ATE123412T1 (de)	1995-06-15
EP0524968B1 (de)	1995-06-07
ES2073164T3 (es)	1995-08-01
DE69110281T2 (de)	1995-11-09
JP3461000B2 (ja)	2003-10-27
PT97101A (pt)	1991-11-29

Publication	Publication Date	Title
NO304576B1 (no)	1999-01-18	FremgangsmÕte for fremstilling av en heterovesikulµr lipidvesikkel eller liposom
EP0280503B9 (de)	2004-04-21	Multivesikuläre Liposomen mit einer eingeschlossenen biologisch aktiven Substanz mit einem Hydrochlorid
EP0729351B1 (de)	2000-09-13	Vesikel mit gesteuerter wirkstofffreisetzung
US6106858A (en)	2000-08-22	Modulation of drug loading in multivescular liposomes
US5422120A (en)	1995-06-06	Heterovesicular liposomes
KR100387561B1 (ko)	2003-10-08	활성제제의조절방출을위한다중소포성리포솜의제법
US5807572A (en)	1998-09-15	Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
KR930700134A (ko)	1993-03-13	이종 소포 리포좀
US5576017A (en)	1996-11-19	Heterovesicular liposomes
JP2008163040A (ja)	2008-07-17	封入された化合物のパーセントが増加したリポソーム
US5173219A (en)	1992-12-22	Uniform spherical multilamellar liposomes of defined and adjustable size distribution
NZ247547A (en)	1996-01-26	Process for preparing heterovesicular lipid vesicles or liposomes; vesicles containing a chloride and an active agent
HK1013259A1 (en)	1999-08-20	Vesicles with controlled release of actives
HK1013259B (en)	2001-05-11	Vesicles with controlled release of actives